Beyond Dystrophin Panel
This conference session provides insight and updates from companies whose therapies target critical aspects of the Duchenne disease process that occur alongside reductions in dystrophin.
Abby Bronson
Vice President, Patient Advocacy & External Innovation
Edgewise Therapeutics
Daniel Paulson, MD
Vice President of Clinical Development
Capricor Therapeutics